NCT04853134View on ClinicalTrials.gov

Proxalutamide Treatment for COVID-19 Female Outpatients

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 1, 2020

Primary Completion Date

December 1, 2021

Study Completion Date

December 1, 2021

Conditions
Covid19SARS-CoV Infection
Interventions
DRUG

Proxalutamide

200 mg q.d.

OTHER

Standard of Care

Standard of care as determined by the PI

Trial Locations (1)

70390-150

Corpometria Institute, Brasília

Sponsors
All Listed Sponsors
lead

Applied Biology, Inc.

INDUSTRY